Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience

Campath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL patients. Campath deserves a special emphasis due to effectiveness in different autoimmune cytope-nias. We describe 2 cases of CLL and autoimmune thrombocytopenia, treated with Campath. Both patients received 36 infusions of Campath. There were no severe leucopenia or anemia as well as serious infections. Stable platelet count recovery, no evidence of antiplatelet antibodies and elimination of bone marrow lymphoid infiltration were achieved after the end of the treatment.